EQL Pharma licenses Memprex UTI drug to Gebro Holding for Spain

PUBT · 1d ago
EQL Pharma licenses Memprex UTI drug to Gebro Holding for Spain
  • EQL Pharma licensed exclusive rights to sell urinary-tract infection prophylaxis Memprex (methenamine hippurate) in Spain to Gebro Holding.
  • Gebro will pay a six-figure EUR amount across six sales-linked milestones; EQL will supply the product under a transfer-price arrangement.
  • The company flagged Spain as an untapped market for methenamine hippurate; UK pharmacy sales for the substance were near EUR 13 million in 2024.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. EQL Pharma AB published the original content used to generate this news brief on July 13, 2026, and is solely responsible for the information contained therein.